Imatinib is a tyrosine kinase inhibitor widely used in the treatment of chronic myelogenous leukemia. Originally designed to target the chronic-myelogenous-leukemia-specific tyrosine kinase bcr ...

Of the compounds Nick sent me for testing, I identified CGP 57148B (also known as STI571, Gleevec, Glivec or imatinib mesylate) as the most effective at killing CML cells without harming normal ...

The company announced the completion of enrollment in its PEAK trial, a pivotal study for patients with imatinib-resistant gastrointestinal stromal tumors, and the initiation of a Phase 1 trial for a ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

Duke-NUS scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

He worked with chemists at Novartis to develop a drug that would bind to the mutant protein like a key in a lock. Novartis ...

A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.

Find all the commercial and brand names of generic drug called Imatinib. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion ...

Novartis has received US Food and Drug Administration (FDA) accelerated approval for Scemblix (asciminib) to treat adults ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The ...